Stryker Corp (SYK)

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whet...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Stryker (NYSE:SYK) and i...

Medical technology company Stryker (NYSE:SYK) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.6% year on year to $6.02 billion. Its no...

Stryker (SYK) Q1 2026 Earnings Transcript

Medical technology company Stryker (NYSE:SYK) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.6% year on year to $6.02 billion. Its no...

Medical technology company Stryker (NYSE:SYK) will be reporting earnings this Thursday after the bell. Here’s what to look for. Stryker beat analysts’ revenu...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&A move in

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of

CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Over the last six months, Stryker shares have sunk to $342.00, producing a disappointing 7.6% loss - worse than the S&P 500’s 1.8% drop. This may have invest...

The company is a picture of financial stability.

As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a "steady Eddie" of the MedTech world that provided everything from basic syringes to complex diagnostic laboratory equipment. However, the recent completion of the Biosciences [...]

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investo...